Literature DB >> 206196

Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs.

A Di Marco, F Zunino, A M Casazza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 206196     DOI： 10.1159/000401466

Source DB:  PubMed          Journal:  Antibiot Chemother (1971)        ISSN： 0066-4758


× No keyword cloud information.
  12 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Phase II trial of idarubicin in patients with advanced lymphoma.

Authors:  H Gillies; R Liang; H Rogers; P Harper; L Parapia; G Cox; S Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

6.  Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.

Authors:  H C Gillies; D Herriott; R Liang; K Ohashi; H J Rogers; P G Harper
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

7.  Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.

Authors:  A Di Marco; A M Casazza; C Soranzo; G Pratesi
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

8.  A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

Authors:  N S Stuart; M H Cullen; T J Priestman; G R Blackledge; C J Tyrrell
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma.

Authors:  H I Scher; A Yagoda; T Ahmed; D Budman; P Sordillo; R C Watson
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.

Authors:  H S Hochster; M D Green; R H Blum; J C Wernz; J L Speyer; F M Muggia
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.